GT Metabolic Solutions
Saint Michael, US · Founded 2020 · 2 known investors
Find your way into GT Metabolic Solutions
Each arrow is one introduction. Sign up to fill in the first one.
Ask Dan Wallace to introduce you to Thierry Thaure
You →Dan · together at Cephea Valve Technologies, Inc. →Thierry
Sign up to find every way you can get introduced to GT Metabolic Solutions
- Your email: who you already know at GT Metabolic Solutions, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the GT Metabolic Solutions team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
GT Metabolic develops magnetic compression anastomosis technology, including its MagDI System, which uses magnets to create incisionless, sutureless duodeno-ileal anastomoses during bariatric surgery. The technique is intended to support weight loss and glycemic control in obese patients with or without type 2 diabetes, and its products have received FDA marketing authorization and clearances.
Founders & leadership


Investors · 2
Reported raises · per SEC filings
Form D private placements$46.5M disclosed across 3 rounds · 2022–2023
▶$23.2MraisedDec 2025 · 201 investors · OtherRule 506(b)
- Thierry ThaureExecutive Officer, Director
- Michel GagnerExecutive Officer, Director
- Offering amount
- $25.4M
- Amount sold
- $23.2M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$4.7MraisedNov 2023 · 31 investors · OtherRule 506(b)
- Michel GagnerExecutive Officer, Director
- Thierry ThaureExecutive Officer, Director
- Offering amount
- $25.4M
- Amount sold
- $4.7M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$18.6MraisedJan 2023 · 88 investors · OtherRule 506(b)
- Michel GagnerExecutive Officer, Director
- Thierry ThaureExecutive Officer, Director
- Offering amount
- $20.2M
- Amount sold
- $18.6M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does GT Metabolic Solutions do?
- GT Metabolic develops magnetic compression anastomosis technology, including its MagDI System, which uses magnets to create incisionless, sutureless duodeno-ileal anastomoses during bariatric surgery. The technique is intended to support weight loss and glycemic control in obese patients with or without type 2 diabetes, and its products have received FDA marketing authorization and clearances.
- Who are GT Metabolic Solutions's investors?
- GT Metabolic Solutions's investors include Healthtech Capital, Krillion Ventures.
- How much funding has GT Metabolic Solutions raised?
- GT Metabolic Solutions has disclosed $46.5M raised across 3 rounds.
- Where is GT Metabolic Solutions headquartered?
- GT Metabolic Solutions is headquartered in Saint Michael, US.

